Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuhei Tara

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Heart and Vessels|March 8, 2021
Gastrointestinal bleeding increases the risk of subsequent cardiovascular events in patients with acute cardiovascular diseases requiring intensive careShin Sakai, Shuhei Tara, Takeshi Yamamoto, et al.
Tissue Engineering. Part C, Methods|April 28, 2015
Hemodynamic Characterization of a Mouse Model for Investigating the Cellular and Molecular Mechanisms of Neotissue Formation in Tissue-Engineered Heart ValvesIyore A James, Tai Yi, Shuhei Tara, et al.
Journal of Cardiology|April 5, 2021
Non-cardiovascular disorders in a contemporary cardiovascular intensive care unit in JapanKosuke Kadooka, Hideki Miyachi, Tokuhiro Kimura, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 8, 2021
Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes MellitusYu Hoshika, Yoshiaki Kubota, Kosuke Mozawa, et al.
ESC Heart Failure|July 8, 2021
Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitusKosuke Mozawa, Yoshiaki Kubota, Yu Hoshika, et al.
Journal of Cardiac Failure|August 23, 2021
Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY TrialYu Hoshika, Yoshiaki Kubota, Kosuke Mozawa, et al.
International Heart Journal|May 31, 2023
Comparison of Percutaneous Coronary Intervention Procedures and Outcomes for Recent and Acute ST-Elevation Myocardial InfarctionYusuke Hosokawa, Takeshi Yamamoto, Shuhei Tara, et al.
Cardiovascular Diabetology|September 26, 2020
Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trialWataru Shimizu, Yoshiaki Kubota, Yu Hoshika, et al.
Acta Biomaterialia|June 15, 2019
Differential outcomes of venous and arterial tissue engineered vascular grafts highlight the importance of coupling long-term implantation studies with computational modelingCameron A Best, Jason M Szafron, Kevin A Rocco, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 10, 2016
TGF-β receptor 1 inhibition prevents stenosis of tissue-engineered vascular grafts by reducing host mononuclear phagocyte activationYong-Ung Lee, Juan de Dios Ruiz-Rosado, Nathan Mahler, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Heart and Vessels|March 8, 2021
Gastrointestinal bleeding increases the risk of subsequent cardiovascular events in patients with acute cardiovascular diseases requiring intensive careShin Sakai, Shuhei Tara, Takeshi Yamamoto, et al.
Tissue Engineering. Part C, Methods|April 28, 2015
Hemodynamic Characterization of a Mouse Model for Investigating the Cellular and Molecular Mechanisms of Neotissue Formation in Tissue-Engineered Heart ValvesIyore A James, Tai Yi, Shuhei Tara, et al.
Journal of Cardiology|April 5, 2021
Non-cardiovascular disorders in a contemporary cardiovascular intensive care unit in JapanKosuke Kadooka, Hideki Miyachi, Tokuhiro Kimura, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 8, 2021
Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes MellitusYu Hoshika, Yoshiaki Kubota, Kosuke Mozawa, et al.
ESC Heart Failure|July 8, 2021
Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitusKosuke Mozawa, Yoshiaki Kubota, Yu Hoshika, et al.
Journal of Cardiac Failure|August 23, 2021
Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY TrialYu Hoshika, Yoshiaki Kubota, Kosuke Mozawa, et al.
International Heart Journal|May 31, 2023
Comparison of Percutaneous Coronary Intervention Procedures and Outcomes for Recent and Acute ST-Elevation Myocardial InfarctionYusuke Hosokawa, Takeshi Yamamoto, Shuhei Tara, et al.
Cardiovascular Diabetology|September 26, 2020
Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trialWataru Shimizu, Yoshiaki Kubota, Yu Hoshika, et al.
Acta Biomaterialia|June 15, 2019
Differential outcomes of venous and arterial tissue engineered vascular grafts highlight the importance of coupling long-term implantation studies with computational modelingCameron A Best, Jason M Szafron, Kevin A Rocco, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 10, 2016
TGF-β receptor 1 inhibition prevents stenosis of tissue-engineered vascular grafts by reducing host mononuclear phagocyte activationYong-Ung Lee, Juan de Dios Ruiz-Rosado, Nathan Mahler, et al.
Pageof 8